Natera (NTRA) Projected to Post Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is expected to be posting its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect Natera to post earnings of ($0.40) per share and revenue of $514.5510 million for the quarter. Natera has set its FY 2025 guidance at EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. During the same period last year, the firm posted ($0.30) earnings per share. The business’s revenue was up 32.2% on a year-over-year basis. On average, analysts expect Natera to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Natera Stock Down 0.9%

Shares of NASDAQ:NTRA opened at $196.45 on Wednesday. The company has a market capitalization of $26.96 billion, a price-to-earnings ratio of -102.85 and a beta of 1.75. The company has a 50 day moving average of $175.77 and a two-hundred day moving average of $162.77. Natera has a 52-week low of $122.08 and a 52-week high of $203.23.

Analysts Set New Price Targets

NTRA has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Wednesday, October 8th. BTIG Research upped their price objective on shares of Natera from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Cowen reiterated a “buy” rating on shares of Natera in a research note on Friday, August 8th. Finally, Piper Sandler reissued an “overweight” rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $194.89.

Insider Activity at Natera

In related news, insider John Fesko sold 928 shares of the business’s stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $191.46, for a total value of $177,674.88. Following the completion of the sale, the insider directly owned 150,699 shares of the company’s stock, valued at $28,852,830.54. The trade was a 0.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Burkes Brophy sold 1,867 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total value of $355,924.88. Following the sale, the chief financial officer owned 64,126 shares in the company, valued at $12,224,980.64. The trade was a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 224,889 shares of company stock worth $43,232,062 over the last quarter. Company insiders own 5.63% of the company’s stock.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co lifted its stake in Natera by 3.7% during the second quarter. CANADA LIFE ASSURANCE Co now owns 38,578 shares of the medical research company’s stock worth $6,523,000 after purchasing an additional 1,390 shares during the last quarter. Resources Management Corp CT ADV lifted its position in shares of Natera by 60.7% in the 2nd quarter. Resources Management Corp CT ADV now owns 654 shares of the medical research company’s stock worth $110,000 after buying an additional 247 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in shares of Natera by 6.6% in the 2nd quarter. Corient Private Wealth LLC now owns 5,796 shares of the medical research company’s stock valued at $979,000 after buying an additional 360 shares during the period. Captrust Financial Advisors boosted its holdings in shares of Natera by 23.3% in the 2nd quarter. Captrust Financial Advisors now owns 13,279 shares of the medical research company’s stock valued at $2,243,000 after buying an additional 2,507 shares during the period. Finally, Vident Advisory LLC grew its position in shares of Natera by 10.1% during the 2nd quarter. Vident Advisory LLC now owns 7,941 shares of the medical research company’s stock valued at $1,342,000 after buying an additional 729 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.